All In Biotech

Drug Trial Radar · NCT01721408

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

A Multicenter, Double-blind, Randomized, Comparison Study Of The Efficacy And Safety Of Tigecycline To Imipenem/Cilastatin To Treat Complicated Intra-abdominal Infections In Hospitalized Subjects.

Last checked: Nov 20, 2026Latest source record: Apr 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

470

Actual

Start

Nov 2012

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a comparative study of the efficacy and safety of tigecycline to imipenem/cilastatin in hospitalized patients with a complicated intra-abdominal infection.

Conditions

  • Intra-abdominal Infection

Interventions

  • TigecyclineDrug

    every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.

  • Imipenem/cilastatinDrug

    every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response at the Test-of-Cure (TOC) Assessment Within the Clinically Evaluable (CE) PopulationTime frame: Day 3, Day 14 or last day of therapy (treatment duration was at least 5 days and up to 14 days), and TOC (14-21 days after the last dose of therapy)
  2. Clinical Response at the TOC Assessment Within the Modified Intent-to-Treat (mITT) PopulationTime frame: Day 3, Day 14 or last day of therapy (treatment duration was at least 5 days and up to 14 days), and TOC (14-21 days after the last dose of therapy)

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • China Meitan General Hospital/General Surgery Department

    Beijing, China

  • Department of General Surgery,Beijing Shijitan Hospital,Capital Medical University

    Beijing, China

  • Navy General Hospital PLA China/Genaral Surgery Department

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Department of General Surgery, Peking Union Medical College Hospital

    Beijing, China

  • Institute of Antibiotics, Hua Shan Hospital, Fudan University

    Shanghai, China

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Zhongshan Hospital Affiliated to Fudan University Qingpu Branch, Department of Surgery,

    Shanghai, China

  • Tianjin Union Medical Center

    Tianjin, China

  • Department of General Surgery, Tianjin Medical University General Hospital

    Tianjin, China

  • Tianjin Nankai Hospital

    Tianjin, China

  • Anqing City Hospital

    Anqing, Anhui, China

  • Department of Hepatobiliary Surgery, Peking University People's Hospital

    Xicheng District, Beijing Municipality, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • Zhangzhou Municipal Hospital of Fujian Province

    Zhangzhou, Fujian, China

  • Department of General Surgery, the First Affiliated Hospital Of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of JiNan University/General Surgery

    Guangzhou, Guangdong, China

  • The First Hospital of Shantou University School of Medicine

    Shantou, Guangdong, China

  • Shenzhen Second People's Hosptial/Department of hepatobiliary surgery

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • HaiKou Municipal People's Hospital

    Haikou, Hainan, China

  • Hainan Provincial People's Hospital

    Haikou, Hainan, China

  • The Third People's Hospital of Hainan Province/department of general surgery

    Sanya, Hainan, China

  • Tongji Medical College, Huazhong University of Science and Technology, The Central Hospital of Wuhan

    Wuhan, Hubei, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University/Intensive Care Unit

    Wuhan, Hubei, China

  • Xiangya Hospital Central-South University/General Surgery

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University/Department of General Surgery

    Changsha, Hunan, China

  • The Third Hospital of Changsha/Department of Surgery

    Changsha, Hunan, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • The Affiliated Jiangyin Hospital of Southeast University Medical College, General Surgery Department

    Jiangyin, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Yangzhou No.1 People's Hospital

    Yangzhou, Jiangsu, China

  • Jilin Province People's Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University/Surgery

    Changchun, Jilin, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Qinghai Provincial People's Hospital

    Xining, Qinghai, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Shanghai Fengxian District Central Hospital, Department of Surgery

    Shanghai, Shanghai Municipality, China

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.